DNMT1 and Myocardial fibrosis: Epigenetic modulators, such as HDAC inhibitors (e.g., Vorinostat, Trichostatin A) and DNMT inhibitors (e.g., Decitabine), are being investigated for their ability to improve myocardial fibrosis and metabolic dysfunction (Ooi et al., 2015; Han et al., 2022).